Microbial API Market Report 2026

The microbial api market size has grown strongly in recent years. It will grow from $67.52 billion in 2025 to $72.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to longstanding use of microbial fermentation in antibiotic production, cost advantages over chemical synthesis routes, established microbial strains for api manufacturing, growing pharmaceutical demand for vitamins and antibiotics, scalability of microbial bioprocesses.

The microbial api market size is expected to see strong growth in the next few years. It will grow to $95.49 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing demand for biologics and complex apis, expansion of vaccine manufacturing capacity, rising focus on sustainable pharmaceutical production, growth of contract manufacturing organizations, continued demand for affordable generic apis. Major trends in the forecast period include growing adoption of microbial fermentation for api production, increasing outsourcing of microbial api manufacturing to cdmos, rising demand for antibiotic and vaccine apis, shift toward cost-effective and scalable bioprocessing methods, expansion of generic microbial apis in global markets.

The increasing prevalence of chronic conditions is expected to drive the growth of the microbial API market in the coming years. Chronic conditions are long-term diseases or health disorders that persist over extended periods and typically require continuous treatment and management. The occurrence of chronic conditions is rising due to factors such as aging populations, sedentary lifestyles, unhealthy diets, environmental changes, and improved disease detection and diagnostic capabilities. The microbial API market supports the treatment of chronic conditions by utilizing therapeutically active compounds derived from microorganisms to develop effective and targeted therapies. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, global cancer cases were projected to exceed 0.035 billion by 2050, reflecting a 77 percent increase from the estimated 0.02 billion cases reported in 2022. Therefore, the growing prevalence of chronic conditions is fueling the expansion of the microbial API market.

Major companies operating in the microbial API market are concentrating on the development of complementary products such as pharmaceutical excipients to enhance drug performance, improve formulation stability, and comply with evolving regulatory and manufacturing requirements. Excipients are inactive substances added alongside active pharmaceutical ingredients to maintain stability, enhance solubility, improve bioavailability, support efficient manufacturing processes, and optimize the overall therapeutic effectiveness of finished drug products. For instance, in October 2023, Clariant, a Switzerland-based chemical company, introduced a new range of VitiPure excipients designed to improve API stability and solubility. These excipients offer formulation solutions for oral, topical, and parenteral applications and act as effective carrier systems for complex drug modalities, including biologics and messenger RNA based therapies, supporting improved delivery, higher bioavailability, and greater formulation flexibility for sensitive pharmaceutical products.

In July 2023, Sartorius Stedim Biotech S.A., a Germany-based bioprocessing company, acquired Polyplus-Transfection SA for an undisclosed amount. This acquisition enhances Sartorius’s upstream reagent and plasmid DNA capabilities by integrating Polyplus’s transfection technologies, which are essential inputs for viral vector and nucleic acid manufacturing processes that align with microbial and fermentation based API production. Polyplus-Transfection SA is a France-based company that provides microbial manufacturing services for active pharmaceutical ingredients.

Major companies operating in the microbial api market are BASF SE, Lonza Group AG, Evonik Industries AG, Royal DSM NV, Catalent Inc., Patheon, Siegfried Ltd., Recipharm AB, Xellia Pharmaceuticals, Shandong Lukang Pharmaceutical Co. Ltd., Tianjin Tianyao Pharmaceuticals Co. Ltd., Henan Topfond Pharmaceutical Co. Ltd., CSPC Pharmaceutical Group Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, AbbVie Inc., Sanofi S.A., Merck & Co. Inc.

Asia-Pacific was the largest region in the microbial API market in 2025. The regions covered in the microbial api market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microbial api market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the microbial api market by increasing the cost of imported fermentation raw materials, culture media, and bioprocessing equipment. These impacts have been most evident in regions dependent on cross-border supply chains, particularly North America and Europe sourcing from Asia-Pacific. Higher input costs have pressured margins for manufacturers. However, tariffs have encouraged local fermentation capacity expansion and domestic api production, strengthening supply security and regional manufacturing ecosystems.

The microbial api market research report is one of a series of new reports that provides microbial api market statistics, including microbial api industry global market size, regional shares, competitors with a microbial api market share, detailed microbial api market segments, market trends and opportunities, and any further data you may need to thrive in the microbial api industry. This microbial api market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Microbial active pharmaceutical ingredients (APIs) are pharmaceutical compounds produced through microbial fermentation or biotransformation processes using microorganisms such as bacteria, yeast, and fungi. These processes are widely used to manufacture essential compounds, including antibiotics and vitamins, and are valued in the pharmaceutical industry for their scalability, cost efficiency, and ability to carry out complex biochemical reactions.

The main types of microbial APIs include antibodies, peptides, proteins, small molecules, and vaccines. An antibody is a protein generated by the immune system that binds to specific targets known as antigens. These APIs can be produced using different host systems, including mammalian, bacterial, and fungal hosts, and at various production sites such as in-house facilities or outsourced manufacturing locations. They include both innovative and generic molecules and are utilized by a range of end users, including pharmaceutical companies, biopharmaceutical companies, and others.

The microbial API market consists of sales of, glycerin, and hydrolyzed yeast protein, salvia sclarea oil, allantoin and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.